Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendment to the Terms of Convertible Loan Stock

8 Dec 2017 07:00

RNS Number : 7627Y
Sopheon PLC
08 December 2017
 

Embargoed Release: 07:00hrs Friday 8 December

 

 

SOPHEON PLC

 

AMENDMENT TO THE TERMS OF CONVERTIBLE LOAN STOCK

 

Sopheon plc ("Sopheon", the "Company" or the "Group") announces that it has reached agreement with the holders of its remaining £1.94m of convertible unsecured loan stock (the "Loan Stock") to convert it into equity by the end of 2017. 

 

As previously announced, in 2009 and 2011, the Company issued a total of £2m of Loan Stock to a group of investors including members of the Board and senior management team. The Loan Stock, which carries an interest coupon at a rate of 8 percent per annum, is currently due to mature on 31 January 2019, and has a conversion price of 76.5p per ordinary share of 20p each in the Company ("Ordinary Shares"). Board members with an interest in the Loan Stock are Barry Mence (£640,000), Andrew Michuda (£45,000), Arif Karimjee (£27,000) and Stuart Silcock (£200,000). Rivomore Limited, a current substantial shareholder in the Company, has an interest in the Loan Stock of £640,000.

 

Proposals have yesterday been put to the holders of the Loan Stock that would reconstitute the instrument such that it would automatically convert to equity on 22 December 2017, at the conversion price stated above, resulting in the issue of 2,535,947 new Ordinary Shares. This change will improve the profile of the Group's year end balance sheet and simplify the capital structure, as well as eliminating the interest charge going forward. In conjunction with this proposed amendment, a one-off payment of 8 percent of the face value of the Loan Stock will be made to holders of the Loan Stock in cash amounting to approximately £155,000, in recognition of the loss of their interest and repayment rights as a result of the early conversion. Irrevocable undertakings have been received from holders representing almost £1.7m of the Loan Stock, being over 85 per cent of the Loan Stock in issue, to vote in favour of a resolution to authorise the amendment of the Loan Stock instrument as described above at a forthcoming meeting of the Loan Stock holders on 22 December 2017 (the "Meeting").

 

The modification of the terms of the Loan Stock constitutes a related party transaction for the purposes of AIM Rule 13. In accordance with the AIM Rules for Companies, Daniel Metzger, as the director independent with respect to this transaction, having consulted with the Company's Nominated Adviser, finnCap Limited, considers that the amendment to the terms of the Loan Stock are fair and reasonable insofar as the Company's shareholders are concerned.

 

Following formal approval by Loan Stock holders at the Meeting, application will be made for the 2,535,947 new Ordinary Shares to be admitted to trading on AIM, and dealings expected to commence on 27 December 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. A further announcement will be made following the Meeting.

 

 

Sopheon's Chairman, Barry Mence said: "I am delighted and grateful that our convertible loan stock holders have continued to show such solid support for the Company, as they have through the last several years of our development as a business. With these changes we will enter 2018 with a clearer capital structure and an enhanced balance sheet."

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener / Camille Gochez (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEADAXELDXFAF
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.